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Abstract
Background:  To compare two strategies of dynamic intensity modulated radiation therapy
(dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the setting of
hypofractionated high-risk prostate cancer treatment.
Methods:  3DCRT and dIMRT/Helical Tomotherapy(HT) planning with 10 CT datasets was
undertaken to deliver 68 Gy in 25 fractions (prostate) and simultaneously delivering 45 Gy in 25
fractions (pelvic lymph node targets) in a single phase. The paradigms of pelvic vessel targeting (iliac
vessels with margin are used to target pelvic nodes) and conformal normal tissue avoidance
(treated soft tissues of the pelvis while limiting dose to identified pelvic critical structures) were
assessed compared to 3DCRT controls. Both dIMRT/HT and 3DCRT solutions were compared to
each other using repeated measures ANOVA and post-hoc paired t-tests.
Results: When compared to conformal pelvic vessel targeting, conformal normal tissue avoidance
delivered more homogenous PTV delivery (2/2 t-test comparisons; p < 0.001), similar nodal
coverage (8/8 t-test comparisons; p = ns), higher and more homogenous pelvic tissue dose (6/6 t-
test comparisons; p < 0.03), at the cost of slightly higher critical structure dose (Ddose, 1–3 Gy over
5/10 dose points; p < 0.03). The dIMRT/HT approaches were superior to 3DCRT in sparing organs
at risk (22/24 t-test comparisons; p < 0.05).
Conclusion: dIMRT/HT nodal and pelvic targeting is superior to 3DCRT in dose delivery and
critical structure sparing in the setting of hypofractionation for high-risk prostate cancer. The pelvic
targeting paradigm is a potential solution to deliver highly conformal pelvic radiation treatment in
the setting of nodal location uncertainty in prostate cancer and other pelvic malignancies.
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Background
Prostate cancer is the most common malignancy to afflict
the Canadian male population. It is estimated that
approximately 20700 men were diagnosed with prostate
cancer in 2006 and approximately 4200 will die of this
disease [1]. Standard curative treatment for high-risk pros-
tate cancer [2] is a radical course of radiation treatment
with long-term androgen suppression therapy [3,4]. A
recently completed RTOG (Radiation Therapy Oncology
Group) prospective randomized phase III trial shows that
whole pelvic nodal irradiation improves biochemical dis-
ease-free survival in patients with a high-risk (>15%) of
positive pelvic lymph nodes from prostate cancer based
on tumour stage, PSA, and Gleason grade [5].
This radiation treatment usually consists of sequential
phases using shrinking fields. Traditionally, the first phase
consists of five daily fractions each week to the whole pel-
vis including the prostate gland and pelvic lymph nodes
at risk using a four-field box technique. The usual pre-
scribed doses range from 44 to 50.4 Gy in 1.8–2.0 Gy frac-
tions. The remainder of the radiation treatment is given to
a reduced boost volume targeting the prostate gland (±
seminal vesicles) using the same fractionation schedule to
a radical total dose. Androgen suppression therapy can be
given in neo-adjuvant, concurrent, and/or adjuvant form
with the radiation [3,4]. Unfortunately, the use of conven-
tionally planned whole pelvic radiotherapy to treat the
whole pelvis results in toxicity to normal structures such
as the small bowel, rectum, and bladder.
Recent studies have illustrated a steep dose response rela-
tionship through escalating the total dose to approxi-
mately 80 Gy (1.8–2.0 Gy per fraction) in intermediate
and high-risk prostate cancer patients. The increasingly
higher doses also intensifies toxicities to the organs at risk
(OARs) which can be partially overcome by using
advanced planning techniques such as IMRT or a concom-
itant boost approach (6–14). However, dose escalation
has not typically been performed in conjunction with pel-
vic nodal radiation. The pelvic dose bath may make it dif-
ficult to safely dose escalate the prostate gland while
respecting normal tissue constraints to the OARs.
Recent literature suggests that prostate cancer may be dif-
ferent than other malignancies in terms of its slow prolif-
eration rate. Labeling indexes can be extraordinarily low,
with most reports suggesting levels below 1%, and longer
potential doubling times with a median Tpot value of 40
days (range 15 to 170) [15]. Traditionally, an alpha:beta
ratio of 10 Gy is used to calculate the biologically equiva-
lent dose (BED) for acute toxicity and tumour response.
Current studies are predicting an alpha:beta ratio of 1.5
Gy (range 0.8–2.2) for prostate carcinoma, below the clas-
sic alpha:beta ratio of 3 to 4 Gy for rectal late radiation
effects [16-22]. This gives a potential therapeutic advan-
tage for hypofractionated RT schedules over conventional
fractionation by escalating the biologically equivalent
dose in a shorter period of treatment time with better
tumour control and reduced rectal toxicity [18,23-25].
Proposed biologically equivalent hypofractionated treat-
ment schedules for prostate cancer have been suggested in
the literature [18-20,24].
The aim of this comparative dosimetric analysis is to eval-
uate two pelvic treatment paradigms of either pelvic vessel
contouring plus margin expansion (pelvic vessel targeting
paradigm) or full pelvic content treatment excluding iden-
tified critical structures (normal tissue avoidance para-
digm) in the setting of hypofractionated treatment of
high-risk prostate cancer. Helical tomotherapy will be
used as the dynamic intensity modulated radiation ther-
apy solution for both treatment solutions. 3DCRT plans
will be used for control comparisons.
Methods and materials
Patients and target/normal tissue contours
A sample of ten patients were scanned on a helical CT
scanner (Phillips 5000) with 3 mm slice thickness with
comfortably full bladder and no bowel preparation prior
to simulation. The prostate and seminal vesicles were
identified and contoured on each patient (by JY) and
reviewed by two clinicians (GR, GB) in order to generate
consensus-based contours. The PTV1 was defined as pros-
tate + 7.5 mm (Figure 1). The nodal target was defined by
a method proposed by Shih et al [26]. The distal common
iliac (2 cm superior to the common iliac bifurcation),
internal iliac (4 cm distal to bifurcation of the common
iliac), and external iliac vessels (to the top of the superior
pubic symphysis) were outlined from L5-S1 to the top of
the symphysis pubis.
The conformal pelvic vessel targeting paradigm was
assessed by generating a lymph node planning target vol-
ume which was defined by a 20 mm radial expansion of
the contoured vessels and tailored to respect the muscle
and bony pelvis normal tissue boundaries up to 10 mm.
Therefore the final PTVcpvt for conformal pelvic vessel tar-
geting included both PTV1 and the lymph node planning
target volume (Figure 1). The conformal pelvic normal tis-
sue avoidance paradigm was assessed by generating a pel-
vic soft tissue target which was defined as the pelvic soft
tissue volume within a standard four field box. This vol-
ume exists between the previously defined lymph node
planning target volume, respecting the normal tissue
boundaries of muscle and bone, and subtracting out all
other identified targets such as small bowel, bladder, rec-
tum, and femora. Therefore, the PTVcnta for conformal
normal tissue avoidance was the PTV1 + lymph node
planning target volume + pelvic soft tissue target (FigureRadiation Oncology 2008, 3:1 http://www.ro-journal.com/content/3/1/1
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1). In both planning cases, the simultaneous in-field
boost (SIB) prostate boost volume would be PTV1.
Rectum, bladder and femoral heads were outlined using
the guidelines provided by the RTOG P-0126 protocol.
Specifically, the entire outer wall of the bladder is con-
toured, the rectum is contoured from the anus (at the level
of the ischial tuberostities) for a length of 15 cm or to
where the rectosigmoid flexure is identified. Femurs
include the femoral head and extend inferiorly to the level
of the ischial tuberosity. Small bowel was contoured in all
slices where the nodal target or pelvic target was identi-
fied. All critical structures were contoured as a single vol-
umetric structure and considered to be solid organs for
dosimetric calculations. A prescription dose of 68 Gy was
prescribed to 95% of the PTV1 in 25 fractions. PTVcpvt and
PTVcnta were prescribed 45 Gy in the same 25 fractions for
both the conformal pelvic vessel targeting and conformal
normal tissue avoidance strategies, respectively.
Helical tomotherapy planning
The dynamic IMRT solution chosen for this dosimetric
feasibility study was helical tomotherapy (TomoTherapy
Inc., Madison, WI, USA). CT datasets and structures were
transferred to the TomoTherapy planning workstation
using the DICOM RT protocol. The TomoTherapy station
re-sampled the CT datasets in 256 × 256 voxels with the
slice thickness re-sampled to the smallest slice separation
in the original CT dataset. The planning system used an
inverse treatment planning process based on iterative least
squares minimization of an objective function [27]. Ini-
tial precedence, importance, and penalty factors were set
(Table 1) to obtain a preliminary helical tomotherapy
plan. Subsequent optimization was based on an assess-
ment of target and OAR dose-volume parameters that
have not been achieved and altering the penalty factors
associated with the target/OAR to drive the plan optimiza-
tion. The solutions must have resulted in deliverable treat-
ment and could not exceed 30 minutes for total treatment
delivery. The dose was calculated using a superposition/
convolution approach [28,29]. Helical delivery is emu-
lated in calculating 51 projections per rotation and the
dose calculation uses a total of 24 different angles for the
dose spread array of the incident 6 MV beam. The optimi-
zation algorithm is deterministic which allowed for the
direct comparison of different strategies. A standardized
class solution with a fan beam width of 11 mm, a pitch of
0.5, modulation factor of 3 and a dose calculation grid of
approximately 4 × 4 × 3 mm3 was used [30].
Three-dimensional conventional planning
3DCRT plans with 18 MV photons were generated using a
commercial treatment planning system, Pinnacle
DCM7.6c (Philips, Amsterdam, The Netherlands). The
plans that were developed used a four-field technique to
treat the pelvis and will serve as the control arm for this
dosimetric study. For the anterior/posterior fields the
superior border was at L5-S1, lateral borders 2 cm lateral
to the widest point of the bony pelvic inlet, and inferior
border 1.5 cm below the prostate on CT images. For the
lateral fields, the anterior border was the anterior surface
of the pubic symphysis, posterior border was the middle
of the sacrum, including at least a posterior 0.75 cm mar-
gin on the prostate and seminal vesicle. Superior and infe-
rior margins were identical to the anterior/posterior fields.
The simultaneous in-field (SIB) prostate boost was treated
with a 6 field coplanar technique targeting the prostate
and proximal seminal vesicle with 1 cm margin. Shielding
using 120 multi-leaf collimation (MLC) was used to shape
the fields.
Statistical methodology
The dIMRT/HT plans were compared to each other and
the 3DCRT in terms of a priori defined target and normal
tissue dose volume histogram (DVH) and dose metric
outcome characteristics (Table 2). The a priori null
hypothesis, for all comparisons, was that the mean values
of DVH parameters/metrics between all three paradigms
were not different. The alternate hypothesis was that the
mean DVH parameters/metrics between all three para-
digms were different. All main comparisons were per-
formed using repeated measures analysis of variance
(ANOVA). All two-way (between any two paradigms)
Example dosimetric volumes used for this study: Target –  Prostate and Prostate/Seminal Vesicles PTVs, Nodal Target,  Pelvic Target; Normal Tissue – Bladder and Rectum Figure 1
Example dosimetric volumes used for this study: Target – 
Prostate and Prostate/Seminal Vesicles PTVs, Nodal Target, 
Pelvic Target; Normal Tissue – Bladder and Rectum.R
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Table 1: Tumor and Normal Tissue Initial Tomotherapy Plan Optimization Parameters
Tumor Constraints
Conformal Pelvic Vessel Targeting
Structure Importance Max Dose (Gy) Max Dose Penalty DVH Volume (%) DVH Dose (Gy) Minimum Dose (Gy) Minimum Dose Penalty
PTV1 10 68 10 95 68 68 33
Rt Iliac Nodal Volume 10 68 1 95 45 45 10
Lt Iliac Nodal Volume 10 68 1 95 45 45 10
PTV1 = prostate + 7.5 mm
Conformal Normal Tissue Avoidance
Structure Importance Max Dose (Gy) Max Dose Penalty DVH Volume (%) DVH Dose (Gy) Minimum Dose (Gy) Minimum Dose Penalty
PTV1 10 68 10 95 68 68 33
PTVcnta 10 68 10 95 45 45 10
PTVcnta = PTV1 + lymph node planning target volume + pelvic soft tissue target
Sensitive Structure Constraints
Structure Importance Max Dose (Gy) Max Dose Penalty DVH Volume (%) DVH Dose (Gy) DVH Penalty
Rectum 1 68 1 40 30 1
Bladder 1 68 1 40 30 1
Lt Femur 1 45 1 50 20 1
Rt Femur 1 45 1 50 20 1
Small Bowel 1 40 1 1 38 1
Field Width = 5.0 cm
Pitch = 0.286
Planning Modulation Factor = 4.0Radiation Oncology 2008, 3:1 http://www.ro-journal.com/content/3/1/1
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post-hoc comparisons were performed using paired Bon-
ferroni adjusted Student's t-tests.
Results
Target structures
The ten CT planning studies represent a wide range of
potential target and normal tissue volumes (Table 3). All
three planning strategies were able to cover 95% of the
PTV1 with the prescription dose. Comparing one plan-
ning process to the other, there are statistically significant
differences in the delivery of dose to this PTV1 (Table 4).
When assessing dose homogeneity as defined as both
D99-D1 and D95-D5, the conformal normal tissue avoid-
ance solution showed the most homogeneous dose distri-
bution compared to the other two strategies. 3DCRT
delivered a higher absolute dose to the nodal target vol-
ume at all dose points (Table 5). However, both dIMRT/
HT plans were able to deliver the prescription dose to the
nodal target while being significantly more homogene-
ous. The pelvic soft tissue target volume looks specifically
at the soft tissues within the pelvic field that excludes the
nodal target and the organs at risk (Table 6). Given the
highly conformal nature of tomotherapy, the conformal
pelvic vessel targeting approach delivered a significantly
lower dose to the pelvic soft tissues, as they were not spe-
cifically targeted. As expected, the 3DCRT and conformal
normal tissue avoidance strategies delivered the highest
dose to the pelvic soft tissue target volume. The conformal
normal tissue avoidance technique had better homogene-
ity of dose compared to the 3DCRT control due to the
IMRT delivery of helical tomotherapy.
Organs at risk
DVH characteristics were compared for the rectum, blad-
der, femoral heads, and small bowel (Table 7). The
3DCRT plan generated the highest dose to all the organs
at risk. The dIMRT/HT techniques were both able to signif-
icantly spare the critical structures better than the non-
conformal control. Within the two dIMRT/HT
approaches, conformal pelvic vessel targeting delivered a
lower dose at most dose points in comparison to confor-
mal normal tissue avoidance.
Dosimetric summary
When compared to conformal pelvic vessel targeting, con-
formal normal tissue avoidance delivered more homoge-
nous PTV delivery (2/2 t-test comparisons; P < 0.001,
Table 4), similar nodal coverage (8/8 t-test comparisons;
p = ns, Table 5), higher and more homogenous pelvic tis-
sue dose (6/6 t-test comparisons; P < 0.03, Table 6), at the
cost of slightly higher critical structure dose (Ddose, 1–3 Gy
over 5/10 dose points; P < 0.03, Table 7). The dIMRT/HT
approaches were superior to 3DCRT in sparing organs at
risk (22/24 t-test comparisons; P < 0.05, Table 7).
Discussion
Intensity modulated radiation therapy (IMRT) uses an
advanced planning technique that creates complex dose
distributions that can deliver a radical dose of radiation to
the prostate gland and treat the pelvic nodes at risk, while
reducing the irradiated volume of small bowel and rectum
[31]. In addition, IMRT can be used to deliver dose to the
primary prostate volume while simultaneously treating
the regional lymph nodes at risk to a lower dose in a single
phase. This strategy, called an SIB technique has many
clinical, dosimetric, and economic advantages and has
been incorporated into several different anatomic sites
[32-39]. Integrating the whole pelvis and prostate boost
into the plan optimization from the outset may, in theory,
improve the likelihood that the resulting solution will be
able to meet the constraints for safe prostate dose escala-
tion in the setting of whole pelvis treatment. By using a
SIB scheme, the prostate gland can be irradiated with a
Table 2: Target and Normal Tissue Dose Metrics Utilized in Study
Volumes of Interest Dose Metrics
Targets PTV1
Lt and Rt lymph node planning volumes
Pelvic soft tissue target volume
D99, D95, D5, D1, D99-D1, D95-D5
OARs Rectum, Bladder D50, D35, D25, D15
Small Bowel D5, D1
Femoral Head D15
PTV = Planning Target Volume; OAR = Organ at Risk, D = Dose
Table 3: Volume Characteristics of 10 Patient CT datasets.
Structure Mean (cm3)S D  ( c m 3) Range (cc)
Prostate 56.86 36.12 30–144.7
Seminal Vesicle 14.82 6.42 3.77–23.5
Bladder 157.65 88.51 63.7–293.4
Small Bowel 244.78 130.89 43.6–496.88
Rectum 102.42 53.51 49.78–227.4
Pelvic Soft Tissues 720.32 241.20 460–1112.6
Left Nodal Target 426.8 61.04 349.33–510.29
Right Nodal Target 419.47 71.07 306.15–538.33
Left Femoral Head 181.38 26.75 151.28–226.66
Right Femoral Head 184.68 28.39 145.6–230.76
SD = Standard DeviationRadiation Oncology 2008, 3:1 http://www.ro-journal.com/content/3/1/1
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Table 4: Dose Volume Metrics of the PTV1
3DCRT Targeting Avoidance ANOVA 3DCRT – Targeting 3DCRT – Avoidance Targeting – Avoidance
D99% 65.18 ± 1.68 65.60 ± 0.59 66.91 ± 0.59 P < 0.001 P < 0.001 P < 0.001 P = 0.001
D95% 68.03 ± 0.97 68.04 ± 0.16 68.06 ± 0.08 P < 0.001 P < 0.001 P < 0.001 NS
D5% 72.15 ± 0.46 71.69 ± 0.35 70.22 ± 1.10 P < 0.001 P < 0.001 P = 0.004 P = 0.005
D1% 72.30 ± 0.47 72.35 ± 0.49 70.84 ± 1.09 P < 0.001 P < 0.001 P < 0.001 P = 0.002
D99%-D1% -7.12 ± 1.63 -6.75 ± 0.95 -3.93 ± 1.63 P < 0.001 NS P = 0.002 P = 0.001
D95%-D5% -4.12 ± 0.92 -3.65 ± 0.34 -2.16 ± 1.09 P < 0.001 NS P < 0.001 P = 0.002
3DCRT = Three Dimensional Conformal Radiation Therapy; Targeting = Conformal Pelvic Vessel Targeting; Avoidance = Conformal Normal Tissue Avoidance; ANOVA = 
Repeated Measures Analysis of Variance
Table 5: Dose Volume Metrics of the Nodal Target Volumes
3DCRT Targeting Avoidance ANOVA 3DCRT – Targeting 3DCRT – Avoidance Targeting – Avoidance
Left Nodal Target Volume
D99% 47.11 ± 0.61 43.49 ± 1.44 44.02 ± 0.86 P = 0.045 NS NS NS
D95% 48.36 ± 0.50 45.41 ± 0.76 45.23 ± 0.50 P = 0.02 NS P = 0.005 NS
D5% 61.13 ± 2.80 49.02 ± 0.90 49.61 ± 1.40 P < 0.001 P < 0.001 P < 0.001 NS
D1% 63.57 ± 3.72 50.74 ± 2.22 51.99 ± 2.87 P < 0.001 P < 0.001 P < 0.001 NS
D99%-D1% -16.45 ± 4.09 -7.25 ± 3.18 -8.42 ± 2.31 P < 0.001 P < 0.001 P < 0.001 NS
D95%-D5% -12.77 ± 3.08 -3.61 ± 1.31 -4.60 ± 1.19 P < 0.001 P < 0.001 P < 0.001 NS
Right Nodal Target Volume
D99% 46.97 ± 0.59 43.29 ± 2.00 43.39 ± 0.74 P = 0.04 NS P < 0.001 NS
D95% 48.22 ± 0.58 45.21 ± 1.01 45.00 ± 0.49 P = 0.03 NS P = 0.005 NS
D5% 61.12 ± 2.25 49.11 ± 0.98 49.65 ± 1.50 P < 0.001 P < 0.001 P < 0.001 NS
D1% 63.90 ± 3.39 51.08 ± 3.34 52.11 ± 3.40 P < 0.001 P < 0.001 P < 0.001 NS
D99%-D1% -16.94 ± 3.48 -7.79 ± 4.66 -9.27 ± 3.37 P < 0.001 P < 0.001 P < 0.001 NS
D95%-D5% -12.91 ± 2.46 -3.90 ± 1.68 -4.91 ± 1.34 P < 0.001 P < 0.001 P < 0.001 NS
Table 6: Dose Volume Metrics for the Pelvic Soft Tissue Target
3DCRT Targeting Avoidance ANOVA 3DCRT – Targeting 3DCRT – Avoidance Targeting – Avoidance
D99% 47.11 ± 0.48 19.58 ± 3.00 41.35 ± 1.30 P < 0.001 P < 0.001 P < 0.001 P < 0.001
D95% 48.32 ± 0.41 27.30 ± 3.00 44.28 ± 1.18 P < 0.001 P < 0.001 P = 0.007 P < 0.001
D5% 62.09 ± 3.14 49.71 ± 1.84 53.49 ± 3.12 P < 0.001 P < 0.001 P = 0.001 P = 0.001
D1% 70.70 ± 1.35 56.53 ± 5.45 58.40 ± 4.44 P < 0.001 P < 0.001 P < 0.001 P = 0.047
D99%-D1% -23.58 ± 1.19 -36.95 ± 6.43 -17.05 ± 3.93 P < 0.001 P < 0.001 P = 0.002 P < 0.001
D95%-D5% -13.77 ± 3.19 -22.41 ± 3.65 -9.21 ± 2.17 P < 0.001 P < 0.001 P = 0.002 P < 0.001
Table 7: Dose Volume Metrics for the Organs at Risk
3DCRT Targeting Avoidance ANOVA 3DCRT – Targeting 3DCRT – Avoidance Targeting – Avoidance
Rectum
D15% 67.68 ± 2.60 59.81 ± 6.44 62.45 ± 4.46 P = 0.004 P = 0.033 NS NS
D25% 63.57 ± 3.62 52.14 ± 5.16 55.27 ± 4.81 P < 0.001 P < 0.001 P < 0.001 NS
D35% 59.39 ± 3.97 46.97 ± 4.58 50.00 ± 4.08 P < 0.001 P < 0.001 P < 0.001 P = 0.04
D50% 54.08 ± 3.22 39.99 ± 5.25 43.76 ± 3.18 P < 0.001 P < 0.001 P < 0.001 P = 0.034
Bladder
D15% 69.14 ± 1.99 62.89 ± 4.61 63.75 ± 3.06 P = 0.004 P = 0.05 P = 0.02 NS
D25% 64.60 ± 5.37 56.01 ± 5.51 57.79 ± 4.43 P < 0.001 P < 0.001 P = 0.001 NS
D35% 60.54 ± 6.44 49.95 ± 6.51 52.61 ± 5.55 P < 0.001 P = 0.001 P = 0.001 P = 0.034
D50% 56.69 ± 5.34 42.40 ± 7.56 44.97 ± 4.83 P < 0.001 P < 0.001 P = 0.002 NS
Femora
LFHD15% 62.84 ± 3.70 40.23 ± 3.64 42.29 ± 1.07 P < 0.001 P = 0.004 P < 0.001 NS
RFHD15% 62.55 ± 3.33 43.08 ± 10.03 41.83 ± 1.34 P < 0.001 P < 0.001 P < 0.001 NS
Small Bowel
D5% 53.47 ± 1.63 42.50 ± 2.02 46.16 ± 2.48 P < 0.001 P < 0.001 P = 0.005 P = 0.002
D1% 54.31 ± 1.57 45.75 ± 2.46 50.00 ± 3.08 P < 0.001 P = 0.001 NS P = 0.003
LFHD = Left femoral head dose; RFHD = Right femoral head doseRadiation Oncology 2008, 3:1 http://www.ro-journal.com/content/3/1/1
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radical hypofractionated dose schedule while the pelvic
nodes would receive a conventionally fractionated tradi-
tional microscopic dose [40].
Using IMRT, a conformal pelvic vessel targeting solution
can be acheived to treat the prostate gland while also treat-
ing the pelvic node bearing regions if the physician can
reliability identify these treatment volumes. In the area of
head and neck radiotherapy, standardized and reliable
anatomic maps for contouring lymph node regions are
available [41,42]. However, no consensus exists for a
standardized identification of pelvic lymph node anat-
omy exists. Currently, contouring of the pelvic vessels has
been used as a surrogate for pelvic nodal regions and used
to generate clinical target volumes. This is usually done by
adding a 1.5 to 2 cm margin around the vessel itself to
approximate the region of the perivascular lymph nodes
[26]. Several potential difficulties exist with this confor-
mal pelvic vessel targeting approach. Firstly, there is
uncertainty as to the optimal margin of normal tissue
around the vessels to adequately cover the lymph node
bearing regions. Secondly, there can be difficulty in the
tracking and visualizing of the internal iliac vasculature.
Finally, there is an inability to target smaller lymphatic
vessels and lymph node regions "in transit" to the larger
nodal stations along the visible vessels.
An alternate strategy proposed in relation to this study is
conformal normal tissue avoidance. In this solution, the
goal is to identify the organs at risk (bladder, small bowel,
rectum, and femoral heads) and subtract them from the
pelvic target volume. The remaining volume is identified
as the target for regional nodal irradiation, which contains
the soft tissues of the pelvis (corresponding to the pelvis
at risk that would be treated by a standard non conformal
pelvic radiation field). Inversely or forward planned opti-
mization can then be designed to treat the pelvic soft tis-
sue target volume to a microscopic dose while limiting
dose to the identified critical structures and dose escalat-
ing the prostate gland. This approach carries the advan-
tage that the critical structures are typically easier to
identify as avoidance volumes rather than the nodal target
regions (which rely on vessels as a surrogate marker). The
conformal normal tissue avoidance strategy would also
allow treatment of smaller lymphatic vessels and lymph
nodes within the pelvic soft tissues with a lower risk of
under-treating important nodal regions. Problems with
this approach include a modest increase in dose to the
organs at risk compared to the conformal pelvic vessel tar-
geting approach and the effect of inter-fraction organ
movement. Multiple CT simulations or daily image guid-
ance with adaptive therapy may be required to clinically
implement a pelvic conformal avoidance strategy. How-
ever it is important to note that doses to the OAR's com-
pare favorably to the calculated and expected doses in
conjunction with 3DCRT four-field pelvic radiation.
In this paper, we attempt to incorporate hypofractiona-
tion, dose escalation, and nodal basin irradiation within a
single-phase dynamic IMRT helical tomotherapy (dIMRT/
HT) solution. Two opposing strategies were studied, con-
formal pelvic vessel targeting and conformal normal tis-
sue avoidance, using the unique capabilities of a
TomoTherapy treatment planning and image-guidance
and IMRT radiation delivery system. Even though both
strategies differ in their approach to the nodal basin, both
solutions delivered the prescribed dose to the prostate and
vessel-defined node bearing regions. The major difference
lies in the dose to the pelvic soft tissues that lie between
the expanded nodal target volume and the organs at risk.
Conformal pelvic vessel targeting does not specifically
address these tissues and subsequently the planning sys-
tem algorithm cannot use this information in developing
a dosimetric plan. The dose is driven into the defined
nodal target and this area essentially becomes a buffer
zone where a dose gradient exists between the vessel tar-
gets and the organs at risk. As such, the planned dose is
significantly less than in the conformal normal tissue
avoidance paradigm where this area is specifically defined
as a target. The planning system optimizes based on the
importance, precedence, and penalty factors to deliver
dose to the pelvic soft tissue target with no such buffer
zone between it and the organs at risk. Therefore, the con-
formal normal tissue avoidance technique was able to
deliver the microscopic dose to the pelvic tissues while
having the benefit of not having to define a nodal target
region based on potentially ill-defined pelvic vasculature.
In addition, the concern of geometric miss associated with
many conformal treatments (due to issues such as motion
of the target) are minimized.
Because conformal normal tissue avoidance targets all the
tissue within the pelvis aside from the organs at risk; it
necessarily delivers a higher dose to the organs at risk
when compared to conformal pelvic vessel targeting
unless they are specifically excluded as a critical structure.
We can see this from the data in table seven, which shows
statistically significant higher doses to these organs at 8/
12 dose points. The absolute differences were about 1–4
Gy over the entire course of treatment, which may be of
limited or no clinical significance in terms of differences
in possible late toxicity. This potential cost to the normal
tissues is necessary to deliver the dose described to the rest
of the pelvis. The clinical impact of this difference in terms
of acute and late effects is currently unknown.
Unfortunately, there are no defined dose limits to OARs in
the setting of hypofractionated treatment of the pelvis.
However, using the linear quadratic concept to calculateRadiation Oncology 2008, 3:1 http://www.ro-journal.com/content/3/1/1
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biological effective doses of different fractionation proto-
cols we can compare our planned doses with the dose lim-
its given for a large RTOG dose escalation trial (Table 8).
The regimens proposed here for hypofractionated dose
escalated treatment of the prostate gland is based on cur-
rently available data. The reliability of each radiobiologic
model will limit our BED. However, even if the α/β of
prostate is 3 instead of 1.5, our planned dose will still
deliver a BED (2 Gy) of 78 Gy. We can see that the
planned doses using both dIMRT/HT strategies are within
the dose constraints given by RTOG P0126. Even so, the
impact on normal tissues of a hypofractionated protocol
where the overall treatment time is significantly less will
need to be defined in current and future clinical trials. In
Canada, a clinical trial is underway evaluating linac based
IMRT and helical tomotherapy, clinically assessing a dose
regimen of 68 Gy in 25 fractions to the prostate while
simultaneously delivering 45 Gy in 25 fractions to pelvic
tissues.
The effects of normal tissue movement are not taken into
account here. While the nature of daily MVCT localization
of the prostate is an inherent benefit to tomotherapy treat-
ment, it currently does not take into account the daily
movement of normal tissues. Ideally, a planning system
powerful enough to develop a solution daily within the
time constraints of a busy treatment facility would be the
ultimate solution. However, as an interim step the con-
cept of adding a margin for tissue movement can also be
used as suggested by the ICRU. We expect that planning
with a more realistic OAR volume will result in a plan that
would lie between the extremes of conformal pelvic vessel
targeting and conformal normal tissue avoidance pre-
sented here. Clinical investigations into the appropriate
definition of the nodal targets are also under evaluation.
For instance, studies into ultra-small super-paramagnetic
iron oxide particles, known generically as ferumoxtran-
10, have been successfully evaluated for detection of sen-
tinel lymph nodes in various clinical trials [43-45]. Ana-
tomic nodal information derived from these studies may
better define the regions at risk within the pelvis to iden-
tify to our treatment planning systems and subsequently
drive the planning system optimization to better cover the
intended targets and to continue to spare the OAR's.
The techniques developed here extend beyond the treat-
ment of prostate cancer. Similar approaches can be used
in other disease sites within the pelvis (cervix,
endometrium, etc). Also, the concepts of conformal nor-
mal tissue avoidance can be generalized to wherever there
is a concern over uncertainties regarding pelvic nodal tar-
get delineation and nearby organs at risk. This technical
dosimetric feasibility study offers evidence that conformal
avoidance, as an advanced treatment planning strategy, is
a potential solution to deliver highly conformal pelvic
radiation in the setting of nodal location uncertainty due
to incomplete nodal mapping or abherent nodal drain-
age.
Conclusion
Therefore this research study has demonstrated that
dIMRT/HT nodal and pelvic targeting is superior to
3DCRT in dose delivery and critical structure sparing in
the setting of hypofractionation for high-risk prostate can-
cer. This technical dosimetric feasibility study offers evi-
dence that conformal avoidance, as an advanced
treatment planning strategy, is a potential solution to
deliver highly conformal pelvic radiation in the setting of
nodal location uncertainty due to incomplete nodal map-
ping or complex nodal drainage.
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